RxDoctor Payments Data

Matthew Crim, MD

Nuclear Cardiology · Athens, GANPI 1588993414

Payments from drug & device makers

$67,832in general payments, 2019–2025

Across 183 payments — averaging $370.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$65K
  • Amgen$573
  • AstraZeneca$319
  • Johnson & Johnson$249
  • E.r. Squibb & Sons, L.L.C.$225
  • Boehringer Ingelheim$165
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,63199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few nuclear cardiology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$194,140
Medicare patients
1,613
Services billed
3,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban423$462,480
EntrestoSacubitril/Valsartan100$143,118
JardianceEmpagliflozin81$111,300
XareltoRivaroxaban101$110,440
Repatha SureclickEvolocumab72$95,710
FarxigaDapagliflozin Propanediol66$72,025
VascepaIcosapent Ethyl47$33,004
Praluent PenAlirocumab28$22,417
BrilintaTicagrelor20$14,739
NexletolBempedoic Acid23$14,469
Ranolazine ErRanolazine37$5,352
Metoprolol Succinate343$4,035
Colesevelam Hcl18$3,868
Atorvastatin Calcium439$3,728
Icosapent Ethyl15$3,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$462,480423 claims
NovartisEntresto$110$143,118100 claims
Boehringer IngelheimJardiance$165$111,30081 claims
Johnson & JohnsonXarelto$249$110,440101 claims
AstraZenecaFarxiga, Brilinta$319$86,76486 claims
Esperion Therapeutics, Inc.Nexletol$71$14,46923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Athens

Where these figures come from

Is this you, or does something look wrong? →